Roche Diagnostics Gmbh

Boehringer Mannheim Gmbh

Other

Hoffmann-la Roche Inc.

Cancerforskningsfonden Af 1989

Ulrich Weidle

Tobias Hildebrandt

Horst Kessler

Helmut Lenz

Marcus Koppitz

Anne Stern

Ulrich Kohnert

Manfred Schmitt

Viktor Magdolen

Herbert Jungfer

Vincent Ellis

Bernhard Konig

Ilse Bartke

Michael Ploug

Brigitte Kaluza

Heinrich Barchet

Keld Dano Slashed

Christoph Riemer

Gottfried Brem

Eberhard Russmann

Heinrich Graeff

Goos Van Muijen

Thomas Gress

Winfred Albert

Sabine Schiemann

Tiberiu Diamantstein

Klaus-Peter Hirth

Markus B&uuml;rgle

Bernhard K&ouml;nig

Goosen Van Muijen

Malte Buchholz

Ulrich Pessara

Stephanie Loesch

Polynucleotide and polypeptide UKW are specific for pancreatic tumors. Diagnosis of UKW is therefore valuable for diagnosis of pancreatic tumors. Antibodies against UKW are, besides their value in diagnosis, useful as therapeutic agents for the treatment of pancreatic tumors.

Methods for diagnosis and therapy of pancreatic cancer and composition useful therein

A process for determining whether or not a cancer cell-containing test sample originating from or containing human cells has potential for tumor development, tumor progression or metastasis, wherein the test sample and a second sample originating from non-tumor cells obtained from the same individual or a different individual of the same species are analyzed by incubating each respective sample with a nucleic probe of sequence SEQ ID NO:1 and determining the approximate amount of hybridization of each respective sample with said probe, and comparing the approximate amount of hybridization of the test sample to an approximate amount of hybridization of said second sample to identify whether or not the test sample contains a greater amount of the specific nucleic acid or mixture of nucleic acids than does said second sample.

Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells

A pharmaceutical composition is disclosed, as well as its use in tumour diagnosis, therapy and prevention, methods for diagnosing, treating and preventing tumours, and antibodies and their use.

Breast carcinoma-associated gene

The present invention concerns a mammalian cell line which when co-cultured with lymphocytes during which allogenic stimulation is avoided activates lymphocytes fo form tumoricidal cells, a process for the production of tumoricidal T lymphocytes by co-culturing lymphocytes with this cell line, the tumoricidal T lymphocytes obtained by means of this process and the use of the cells according to the present invention for the production of a therapeutic agent which can be used in tumour therapy.

Tumoricidal T lymphocytes

Monoclonal antibodies against the interleukin 2 receptor

Inhibitors for urokinase receptor

A nucleic acid molecule (URIM) with the nucleic acid sequence SEQ ID NO:1 is capable of inducing tumor progression and/or metastasis. The URIM protein of SEQ ID NO:2 is also provided. A process for determining whether a tumor sample has metastatic potential is provided.

Nucleic acid which is upregulated in metastatic human tumor cells

For the production of hetero-bispecific monoclonal antibodies at least the genes for the light chain and for the variable part of the heavy chain are isolated from a hybridoma cell line which secretes an antibody with a desired specificity and they are inserted into a eukaryotic plasmid vector which contains a marker capable of selection together with a strong promoter, this expression vector is transfected into a hybridoma cell line which secretes antibodies with a second desired specificity, the cell line is cultured, the antibodies are obtained and the bispecific antibody is isolated.

Process for the production of hetero-bispecific antibodies

The invention relates to an antibody which inhibits the binding between u-PA and u-PAR to an extent of at least 90% in an assay as defined in the specification, or an active fragment or immunological equivalent of said antibody. Examples of such antibodies are deposited Jul. 7, 1994 at Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSM) with accession numbers DSM ACC2178 and DSM ACC2179 under the terms and conditions of the Budapest Treaty. The invention furthermore relates to a method for detecting or quantifying u-PAR or a glycosylation variant of u-PAR in a sample by use of an antibody according to the invention. Furthermore, the invention relates to a method for the manufacture of a therapeutic agent for preventing or counteracting localized proteolytic activity using of an antibody of the invention as well as to use of an antibody according to the invention for the preparation of a diagnostic agent which is capable of targeting a diagnostic to a cell that contains a u-PAR on the surface.

Hydrophobic u-PAR binding site

Process for the production of proteins with antibody activity in which one or several DNA sequences coding for this protein are introduced into the male pronucleus of a fertilized ovum of a pig or rabbit by microinjection, the ova are implanted in the oviduct of a pig or rabbit, the offspring are bred and the protein with antibody activity is isolated from their serum in the usual way whereby the DNA sequences used for the microinjection are free of bacterial foreign sequences, and are preferably used with immunoglobulin promoter and enhancer sequences.

Process for the production of antibodies

t-PA mutant GK1L

The present invention provides a vector for the expression of heterologous proteins in mammalian cells, wherein it contains at least one first consensus sequence is homologous to the ##STR1## in at least 10 nucleotides in total and including the first three thereof and at least one second sequence which in one of the 6th, 8th, 9th and 10th nucleotide, as well as in at least 9 nucleotides, is homologous to the sequence ##STR2## or in at least 10 nucleotides is homologous to the sequence

Murine autonomous replication sequences and vectors containing

Growing community of inventors

Munich, Germany

Ulrich Weidle